Cellectar Biosciences found using ticker (CLRB) have now 6 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 10 and 3 calculating the average target price we see 5.98. Now with the previous closing price of 1.98 this indicates there is a potential upside of 202.0%. The 50 day moving average now sits at 2.01 while the 200 day moving average is 1.45. The company has a market capitalisation of $55m. Find out more information at: http://www.cellectar.com
Cellectar Biosciences, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics and changed its name to Cellectar Biosciences in February 2014. Cellectar Biosciences was founded in 2002 and is headquartered in Florham Park, New Jersey.